Benchling announced Benchling Biologics, an end-to-end platform for antibody R&D, today at the PEGS Boston Summit. Scientists ...

GaluxDesign achieved the broadest target coverage among publicly comparable de novo antibody design studies, identifying ...

Over decades, antibodies have established themselves as a key therapeutic modality for a wide range of diseases. But antibodies as they are found in nature did not evolve to be used as drugs, says ...

Antibody therapeutics are a rapidly growing class of drugs used to treat infections as well as a range of diseases. Among them are cancer and autoimmunity particularly important, and the use of ...

Antibodies have evolved by nature to possess exquisite selectivity for foreign targets to elicit an effective immune response, making particularly promising strides in advancing drug development for ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...

(Nanowerk News) A new artificial intelligence-driven pipeline developed in a collaborative research combines protein structure prediction, sequence design, and live-cell screening together to enable ...

Using AI and Multiplexed Gene Fragments, researchers developed a novel design approach to encode thousands of single-domain antibodies without compromising sequence integrity. Monoclonal antibodies ...

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...